Clinical Trial

Strategy for Withdrawal of Pharmacological Treatment for Urinary Incontinence in Children (StayDry)

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The primary objective is to investigate if abrupt withdrawal versus gradual withdrawal of pharmacotherapy (solifenacin and/or mirabegron) influences the risk of recurrence of incontinence. Children aged 5-14 years diagnosed with urinary incontinence, treated with pharmacotherapy of solifenacin and/or mirabegron and ready for withdrawal will be randomized 1:1 to either abrupt or gradual withdrawal, according to the medical treatment that the child is receiving.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-06-13; most recent amendment 2026-06-04.
Status change: Recruiting → Active, Not Recruiting 2026-06-04
Trial Details
NCT Number NCT06465576
Lead Sponsor University of Aarhus
Conditions Urinary Incontinence in Children
Enrollment 216 participants
Start Date 2024-05-27
Primary Completion 2027-12-01 (estimated)
Study Completion 2027-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-08